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In humans the repeated use of amphetamine (AMPH) produces a hypersensitivity to the psychotogenic effects of AMPH that per- 
sists for months to years after the cessation of drug use. To explore the neurobiological basis of this phenomenon the long-term effects 
of dextroamphetamine ((+)-AMPH) on brain monoamines and behavior were studied in an animal model of AMPH lbsychosis. An es- 
calating dose pretreatment regimen (from 1 to 10 mg/kg over 5 weeks) was used to mimic the pattern of drug use associated with the de- 
velopment of addiction and AMPH psychosis. The effect of pretreatment with AMPH on dopamine (DA) release in the ventral stria- 
turn (nucleus accumbens) was determined by measuring the extracellular concentrations of DA and DA metabolites using in vivo mi- 
crodialysis, both before and after an AMPH challenge. The postmortem tissue concentrations of DA, serotonin and their metabolites 
were measured to determine if this treatment was neurotoxic. Escalating doses of (+)-AMPH were not neurotoxic, and 25-30 days af- 
ter the cessation of drug treatment animals showed relatively normal levels of spontaneous motor activity across the day-night cycle. 
However, AMPH pretreatment produced robust behavioral sensitization. Animals showed a marked hypersensitivity to the motor 
stimulant effects of an AMPH challenge, even after 15-20 days of withdrawal. Most importantly, this hyperdopaminergic behavioral 
syndrome was accompanied by significantly elevated DA release in the ventral striatum. In contrast, AMPH pretreatment had no ef- 
fect on the ~oasal extracellular concentrations of DA. It is suggested that the sensitization produced by chronic AMPH use is due to en- 
during changes in the releasability of DA, and that this may represent an example of neural plasticity common to other forms of behav- 
ioral adaptation. 
INTRODUCTION 
People who abuse psychomotor stimulant drugs, 
such as amphetamine (AMPH)  or cocaine, frequent- 
ly develop a drug-induced paranoid psychotic condi- 
tion characterized by delusions of persecution, hallu- 
cinations, affective disturbances and perseverative 
behavior 6'9'4°. A M P H  psychosis usually dissipates 
upon the cessation of drug use, but there are also 
long-term sequelae associated with A M P H  abuse. 
For example, re-exposure to a relatively low dose of 
AMPH will often precipitate a psychotic episode in 
former A M P H  addicts who have been abstinent for 
months to years 35'36,46. The enduring hypersensitivity 
to AMPH seen in former addicts suggests that 
chronic AMPH use has long-term effects on brain 
function. 
A number  of animal models have been developed 
to study the neurobioiogical consequences of chronic 
AMPH treatment.  For example, A M P H  addicts fre- 
quently take very high doses of A M P H  in ' runs '  that 
can last for 4 - 6  days 21, and some researchers have at- 
tempted to capture this pattern of use by repeatedly 
administering very high doses of A M P H  ( ~ 1 0 - 2 0  
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mg/kg) 2 - 6  times a day 13'19'25'27A3'44'45. Others  have 
continuously mainta ined e levated blood levels of 
A M P H  with a slow-release subcutaneous implant  12. 
These two approaches  are usually neurotoxic,  pro- 
ducing a permanent  deplet ion of dopamine  (DA)  and 
serotonin (5-HT) in selected brain regions ll'3° (cf. 
ref. 48). A third approach has been to repeatedly  and 
intermittently administer  a constant  low dose of 
A M P H  ( ~ 1 - 5  mg/kg) no more than twice a day. This 
latter t reatment  regimen is not neurotoxic,  but pro- 
duces a progressive and enduring enhancement  (sen- 
sitization) in the motor  st imulant effects of A M P H  24' 
30,~2 and in AMPH-s t imula ted  striatal D A  release in 
vitro 20'29"31'49. It has been argued that the phenome-  
non of behavioral  sensitization provides a good ani- 
mal model  of AMPH psychosis 3°'4°. 
Nevertheless,  A M P H  addicts initially take rela- 
tively low doses of A M P H ,  using higher doses only as 
they become tolerant  to the euphorigenic  and auto- 
nomic effects of A M P H  7"1°'1s'21, and none of the ap- 
proaches for studying chronic A M P H  t rea tment  
ment ioned above take this escalating pat tern of 
A M P H  use into account. It may be impor tant  to do so 
because the neurochemical  effects of high doses of 
A M P H  are changed by pre t rea tment  with escalating 
doses of A M P H  37'3s. The present  exper iments  were 
conducted,  therefore,  to de termine  the long-term ef- 
fects of escalating (but non-toxic) doses of A M P H  
on: (1) regional brain concentrat ions of D A ,  5-HT 
and their  major  metabol i tes ;  (2) spontaneous  motor  
activity across the day -n igh t  cycle; and (3) in vivo 
extracellular  concentrat ions of D A ,  dihydroxy- 
phenylacetic acid ( D O P A C ) ,  homovanil l ic  acid 
(HVA) and 5-hydroxyindoleacet ic  acid ( 5 - H I A A )  in 
the ventral str iatum (nucleus accumbens) ,  both be- 
fore and after a challenge injection of A M P H  in free- 
ly moving rats. The ventral str iatum was chosen for 
study because it has been implicated in the motor  
stimulant,  affective, and rewarding effects of psycho- 
motor  stimulant drugs 14"5°. 
MATERIALS AND METHODS 
Subjects and pretreatment regimen 
Adul t  female Hol tzman rats (Hol tzman,  Madison,  
WI) were housed individually in a tempera ture-con-  
trolled room on a normal  l ight:dark cycle (14:10 h, 
with lights on at 08.00 h), and with free access to food 
and water.  Each rat received 2 daily in t raper i toneal  
injections of ei ther 0.9% saline or (+ ) - a mphe t amine  
sulfate ( A M P H ) ,  with 8 -10  h separat ing the two in- 
jections. Af ter  each injection the animals were 
placed back into their home cages and left undis- 
turbed.  Injections were given on consecutive week-  
days, but not on weekends,  and animals p re t rea ted  
with A M P H  received increasing doses of A M P H  ac- 
cording to the schedule i l lustrated in Table i. Follow- 
ing the last injection of A M P H  or saline the animals 
were left in their  home cages until used in one of the 
two exper iments  described below. 
Experiment 1. The effects of pretreatment with escalat- 
ing doses of A M P H  on spontaneous motor activity 
and postmortem tissue concentrations of monoamines 
and monoamine metabolites 
Twenty-five days after the last p re t rea tment  injec- 
tion of A M P H  or saline the animals were t ransferred 
from their  home cage to au tomated  activity moni tors  
(41 x 24 x 18 cm), which are described in detail  else- 
where 33. The monitors  detect  movement  from one 
end of the cage to the other  ( locomotion) ,  and are not 
sensitive to small movements  of the head or body 
made in one location. The animals remained  in these 
monitors for 24 h/day for the next 5 days, and the 
number  of photocel l  beam interrupt ions each animal 
made was cumulated over  30 min intervals for 20 
h/day. The l i gh t -da rk  cycle was the same as in the 
main colony room. Af ter  this the animals were 
placed back into their  home cages. 
Three to four days later  the animals were killed 
rapidly by decapitat ion.  Each brain was removed 
TABLE I 
Amphetamine pretreatment regimen 
The numbers represent mg/kg of AMPH per injection (weight 
of the salt) on each pretreatment day. Animals received two 
injections/day (see Methods). 
Week Day' 
M T W Th F Sa Su 
1 l 1 2 2 2 - - 
2 3 4 4 4 4 - - 
3 4 5 5 5 5 - - 
4 6 7 7 7 7 - 
5 8 9 9 9 9 - 
6 9 10 10 10 10 - 
from the cranium (30-45 s), placed into ice-cold sa- 
line for approx. 30 s, and then placed in a chilled cut- 
ting block. Coronal sections were obtained as de- 
scribed by Heffner et al. ~7 and the following regions 
dissected in ice-cold saline. (a) Frontal cortex. This 
consisted of the DA-rich anteromedial portion of the 
frontal cortex, from just anterior to the genu of the 
corpus callosum to the frontal pole. (b) Striatum. The 
corpus of the striatum was removed with a 3 mm 
diameter micropunch. (c) Nucleus accumbens. The 
nucleus accumbens was removed with a 2 mm diame- 
ter micropunch. (d) Hypothalamus. The entire hypo- 
thalamus was dissected as described by Heffner et 
al.17. Tissue from the left and right hemispheres was 
pooled, weighed, placed into tubes containing 0.05 N 
HCIO4, with dihydroxybenzylamine added as an in- 
ternal standard, and then homogenized. Samples 
were centrifugedat 5,000 g for 45 min at 2 -4  °C, the 
supernatant filtered through 0.45 ~tm syringe filters 
(Gelman Sciences, LC3A) and stored frozen at 
-20 °C until assayed for dopamine (DA), dihydroxy- 
phenylacetic acid (DOPAC),  homovanillic acid 
(HVA), 5-hydroxytryptamine (5-HT) and 5-hy- 
droxyindoleacetic acid (5-HIAA) by HPLC-EC, as 
described previously 32. 
Experiment 2. The effects of  pretreatment with escalat- 
ing doses of  A M P H  on behavior and the concentra- 
tions of DA, DOPA C, HVA and 5-HIAA in ventral 
striatal extracellular fluid in vivo, both before and af- 
ter an A M P H  challenge 
Fifteen to 21 days after the last pretreatment injec- 
tion of AMPH or saline matched pairs of animals 
(one AMPH and one saline-pretreated) were anes- 
thetized with sodium pentobarbital, supplemented 
with methoxyflurane, and placed into a stereotaxic 
instrument. Using standard stereotaxic techniques, a 
microdialysis probe was lowered into the ventral 
striatum in either the left or right hemisphere (half 
the animals received an implant on the left and half 
on the right). The term ventral striatum is used ac- 
cording to the terminology for brain DA systems sug- 
gested by BjOrklund and LindvaW, and takes into 
account the concept of a ventral striatal region intro- 
duced by Heimer and Wilson 16, consisting primarily 
of the nucleus accumbens and tuberculum olfactori- 
urn. During implantation a modified Ringer solution 
(147 mM Na +, 2.3 mM Ca 2+, 4 mM K + and 155.6 
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mM CI-, pH 6.0) flowed continuously through the 
probe at approximately 1.0 pl/min. The dialysis 
probe was fixed to the skull with stainless steel screws 
and dental acrylic, and the entire assembly was en- 
cased in a protective housing constructed from the 
dental acrylic. The inlet and outlet tubing was 
threaded through a coiled steel tether, and the inlet 
line connected to a single channel liquid swivel (In- 
stech Laboratories, Plymouth Meeting, PA). The an- 
imals were then placed into a 29 × 29 × 31 cm high 
plexiglass test chamber and left there overnight, dur- 
ing which time Ringer solution was continuously 
pumped through the probes at 0.2pl/min using a Har- 
vard Model 22 syringe pump and 2.5 ml gas-tight 
Hamilton 1000 series syringes. 
The dialysis probes and method have been de- 
scribed in detail previously 34. Briefly, the dialysis 
probe was of a concentric design and consisted of a 
2.0 mm length of regenerated cellulose hollow dialy- 
sis fiber (Spectrum), which had an o.d. of 250~m and 
M.W. cut-off of 6000. The outlet tube consisted of a 
30 cm length of fused silica capillary tubing (Polymi- 
cro Technologies, Phoenix, AZ) with an o.d. of 150 
um and an i.d. of 75 pm. Dialysate was collected in 
minivials mounted on the tether approx. 25 cm above 
the animal and could be quickly exchanged without 
touching the animal. Prior to implantation all probes 
were tested for their ability to recover known con- 
centrations of DA, DOPAC, HVA and 5-HIAA in 
vitro, at 37 °C and a flow rate of 1.5/,tl/min 34. 
Eighteen to 20 h after probe implantation the 
pump speed was set to 1.5 ~d/min, and after waiting at 
least 30 rain, dialysate samples were collected over 
20 min intervals in tubes containing 10 ktl of 0.05 N 
HC104, also containing 0.1 mM sodium bisulfite and 
0.2 mM EDTA per 25 ml of HCIO4. At least 3 base- 
line samples were collected and then each animal re- 
ceived a challenge injection of 2.0 mg/kg of (+)-  
AMPH, and an additional 10 samples collected. This 
challenge dose was used because it was previously 
shown to be effective in behaviorally differentiating 
sensitized and control animals 33. Dialysate was in- 
jected directly onto the HPLC column within 10 min 
after collection and without further treatment, using 
assay procedures described by Robinson and Whi- 
shaw 34. 
The test chambers were located in a separate 
room, adjacent to the neurochemistry lab, and white 
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noise was played continuously to mask sounds from 
nearby rooms. The animals were left undisturbed in 
this room, but were monitored from the neurochem- 
istry lab by closed-circuit television. The experi- 
menter entered the test room periodically only to 
quickly change sample collection vials. 
The animals were video-taped during one 20 min 
baseline interval, and for 200 min following the 
AMPH challenge. Behavior was analyzed later by 
viewing the videotapes, often at 2 -8  x normal 
speed. Locomotor  activity was estimated by counting 
the number of times an animal moved from one side 
of the cage to the other (crossovers), and the number 
of times an animal reared (both front feet off the 
ground), during consecutive 10 min intervals. Stereo- 
typed behavior was quantified by an observer blind 
to pretreatment condition, who rated the occurrence 
of repetitive head and limb movements,  and repeti- 
tive sniffing behavior, at the half-way point of each 
20 min collection interval. Head and limb movements 
were rated as: 0 = no head movements,  or head 
movements associated with normal locomotion; 1 = 
increased frequency of otherwise normal appearing 
head movements associated with hyperactivity; dis- 
continuous; mild intensity; 2 = stereotyped (repeti- 
tive) up and down head movements and shuffling of 
the forepaws; discontinuous; 3 = continuous, in 
place, repetitive head and limb movements;  moder- 
ate intensity and frequency; 4 = as 3, but high inten- 
sity and frequency. Sniffing was rated as: 0 = no 
sniffing, or a normal pattern of sniffing associated 
with breathing or normal exploration of an object or 
place; 1 = increased rate of sniffing associated with 
increased locomotion and rearing (hyperactivity); 
discontinuous; mild intensity; 2 = stereotyped sniff- 
ing (repetitive vibrissae and snout movements);  dis- 
continuous; not directed at a specific object or place; 
moderate intensity; 3 = continuous, in place repeti- 
tive vibrissae and snout movements;  moderate inten- 
sity and frequency; 4 = intense, continuous vibrissae 
and snout movements aimed at the cage floor. 
At the completion of the dialysis experiment the 
animals were killed with an overdose of sodium pen- 
tobarbital and perfused through the heart, first with 
0.9% saline, followed by 10% formalin in saline. The 
brains were removed and stored in 10% formalin. 
They were later frozen and horizontal sections pre- 
pared using standard histological techniques. The 
sections were stained with cresyl violet and examined 




Behavior. Fig. 1 shows the average locomotor ac- 
tivity counts for saline and AMPH-pre t rea ted  rats 
cumulated over 30 min intervals for 7.5 h prior to 
lights-off, the 10 h lights-off period, and then an addi- 
tional 2.5 h after the lights came on. Data for the re- 
maining 4 h were not included to minimize the distur- 
bance associated with daily feeding, cage cleaning 
and data collection (printing). To reduce intrasubject 
variability in activity associated with the estrous 
cycle, the data were averaged over the 5 days of test- 
ing, during which time each animal would have had 
only one complete cycle. 
Both groups showed a similar pattern of motor  ac- 
tivity across most of the l ight-dark cycle. Activity 
levels were low during the afternoon, but rose slowly 
prior to lights off. There was a marked increase in lo- 
comotor  activity when the lights initially went off. 
Activity subsided from this initial high to a low point 
5 h after lights-off, but still remained higher than dur- 
ing the day. There was no difference between saline 
and AMPH-pretreated animals when all 40 intervals 
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Fig. 1. The average frequency of photocell beam interruptions 
(crossovers) cumulated over 30 min intervals across the day- 
night cycle in amphetamine-pretreated (closed circles) and sa- 
line-pretreated (open circles) rats. The lights-off period, which 
started at 10.00 h and ended at 08.00 h, is illustrated by the 
thick black line on the horizontal axis. 
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TABLE I[ 
Average (+ S. E.M.) regional concentrations (ng/mg wet tissue weight) of monoamines and monoamine metabolites in postmortem tissue 
obtained from amphetamine (AMPH)- and saline-pretreated rats 
Compound Pretreatment Striatum Accumbens Cortex Hypothalamus 
D A  Saline 14.23 + 0.43 9.76 + 0.34 0.022 + 0.007 0,661 _+ 0,036 
A M P H  13.22 + 0.53 9.41 + 0.33 0.028 + 0.009 0.678 _+ 0.028 
D O P A C  Saline 1.11 + 0.06 1.21 + 0.08 0.057 + 0.007 0.616 + 0.033 
A M P H  1.08 + 0.05 1.28 + 0.05 0.065 + 0.009 0.679 _+ 0,042 
HVA Saline 0.978 + 0.065 0,791 + 0.063 0,073 + 0.010 - 
A M P H  1.055 + 0.073 0.854 + 0.042 0,064 + 0.007 - 
5-HT Saline 0.420 + 0.030 0,893 + 0.103 1.85 + 0.11 1.83 _+ 0.09 
A M P H  0.436 + 0,035 1.041 + 0.133 1.88 + 0.12 1.82 _+ 0.10 
5 - H I A A  Saline 0.614 + 0.019 0,733 + 0.069 0.729 + 0.052 0.946 _+ 0.048 
A M P H  0.616 + 0.014 0,904 + 0.067 0,771 + 0.050 0.913 _+ 0.025 
tivity was analyzed (2-way ANOVAs  with repeated 
measures). AMPH-pre t rea ted  animals, however,  
tended to be less active than saline-pretreated con- 
trois towards the end of  the dark period (2-way 
A N O V A  on the last 2 h of nocturnal activity; Fl,18 = 
4.24, P = 0.054, main effect). This was because sa- 
line-pretreated rats showed a statistically significant 
increase in activity from the low point during the 
middle of the night (02.30-03.00 h) to the last inter- 
val before lights on (1-way A N O V A  for repeated 
measures, F10,90 = 2.65, P = 0.007), whereas 
AMPH-pre t rea ted  rats did n o t  (F10,90 --- 1.69, P = 
0.095; Fig. 1). 
Neurochemistry. Table II  shows the average post- 
mortem tissue concentrations of DA,  D O P A C ,  
HVA, 5-HT and 5 - H I A A  in the striatum, nucleus ac- 
cumbens, frontal cortex and hypothalamus,  mea- 
sured 33-34 days after the last pretreatment injec- 
tion. There was no difference between the saline and 
AMPH-pret rea ted  groups on any measure, in any 
structure (t-tests). The D O P A C / D A ,  H V A / D A  and 
5-HIAA/5-HT ratios for each structure were also 
analyzed, and again there was no significant effect of 
A M P H  pretreatment.  
Experiment 2 
Behavior. There was no difference in activity be- 
tween saline- and AMPH-pre t rea ted  animals during 
baseline testing, and animals from both groups were 
very inactive as indicated by low levels of  locomotion 
and rearing (Fig. 2). This was expected because test- 
ing took place during the lights-on period, and after 
the animals had been in the chambers for 18-20 h. 
The animals typically sat still, sometimes making 
small head movements,  grooming or walking; but 
frequently they appeared to be asleep (curled immo- 
bile posture). They would often maintain this sleep- 
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Fig. 2. The effects of pretreatment with saline (open symbols) 
or amphetamine (closed symbols) on behavior before and after 
a challenge injection of 2.0 mg/kg of amphetamine given 15-21 
days after the last pretreatment injection. The frequency of 
crossovers (locomotion from one side of the cage to the other) 
and rearing was cumulated over 10 min intervals, and the arrow 
in the upper left panel indicates when AMPH was given. Ste- 
reotypy ratings were obtained once during each 20 rain interval 
(see Methods). B represents the average values obtained dur- 
ing baseline and the remaining symbols the average values ob- 
tained after the amphetamine challenge. For the stereotypy 
ratings ___ S.E.M. bars are also shown. Amphetamine-pre- 
treated animals differed significantly from saline-pretreated 
animals on all measures (see text). 
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In contrast, pretreatment  condition had a large ef- 
fect on the behavior produced by a challenge injec- 
tion of 2.0 mg/kg of AMPH.  In control animals 
AMPH caused marked hyperactivity, as indicated by 
high levels of locomotion and rearing (Fig. 2). The 
amount of locomotion and rearing increased quickly 
after the AMPH challenge, reaching a peak during 
the second 10 min interval after the injection. Al- 
though locomotion and rearing slowly declined over 
the remainder of the test session, motor activity re- 
mained higher than during baseline throughout the 
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Fig. 3. The average (_+ S.E.M.) extracellular fluid concentra- 
tions of dopamine (A), DOPAC (B; dihydroxyphenylacetic 
acid), HVA (C; homovanillic acid) and 5-HIAA (D; 5-by- 
droxyindoleacetic acid) in ventral striatum in vivo, before (B) 
and after (20 min intervals, 1-10) a challenge injection of 2.0 
mg/kg of amphetamine in rats that were pretreated with am- 
phetamine (closed symbols) or saline (open symbols). All dia- 
lysis probes were tested for their ability to recover known con- 
centrations of DA, DOPAC, HVA and 5-HIAA in vitro, and 
the values shown (in fmol/min) were corrected for recovery. 
The average relative recovery values were: DA - -  18.8 + 
0.7%, DOPAC-- 17.2 _+ 0.8%; HVA-- 16.8 + 1.1%; and 5- 
HIAA - -  16.3 _+ 0.9%. The amphetamine challenge produced 
a significantly greater increase in extracellular DA in ampheta- 
mine-pretreated than in saline-pretreated rats. The results of a 
two-way analysis of variance for repeated measures on each 
compound were as follows: DA - -  effect of pretreatment, FL] 3 
= 5.45; P = 0.036; effect of time, Fto.13o = 30.3, P < 0.001 ; pre- 
treatment × time interaction, Fro.L30 = 3.44; P < 0.001 ; *, P < 
0.05, Scheffe tests. DOPAC - -  pretreatment, F - 6.43, P = 
0.025; time, F = 33.6, P < 0.001; interaction, F <  1.0, non-sig- 
nificant (n.s.). H V A -  pretreatment, F = 2.91, P = 0.11; time, 
F = 21.5, P < 0.001 : interaction, F < 1.0, n.s. 5-HIAA - -  pre- 
treatment, F - 1.51, P = 0.24; time, F < 1.0, n.s. ; interaction, 
F< 1.0, n.s. 
rest of the session. Hyperactivity was accompanied 
by an increase in sniffing behavior, but saline-pre- 
treated animals did not develop focused stereotyped 
behavior - -  as indicated by maximal average stereo- 
typy scores of only about 2.5 for sniffing and 1.0-1.5 
for head and limb movements  (Fig. 2). AMPH-pre-  
treated rats, however, showed a behavioral syn- 
drome typical of a higher dose of AMPH 42. In this 
group the AMPH challenge produced an initial ele- 
vation in locomotion and rearing lasting for 20-30 
min, followed by a precipitous drop in locomotor ac- 
tivity to very low levels during the period lasting ap- 
proximately 50-90 min after the injection (Fig. 2). 
During the period of reduced locomotor activity 
AMPH-pretreated rats showed intense focused ste- 
reotyped behavior - -  as indicated by average stereo- 
typy ratings of approximately 3.5 (Fig. 2). This ste- 
reotypy phase was followed by a period of 'post-ste- 
reotypy hyperactivity '>,  during which time the inci- 
dence of locomotion again increased (Fig. 2). Thus, 
animals pretreated with escalating doses of AMPH 
and given a challenge injection of 2.0 mg/kg of 
AMPH showed a multiphasic behavioral syndrome 
characteristic of highly sensitized animals > . 
In vivo microdialysis.  The changes in behavior 
produced by pretreatment  with AMPH were accom- 
panied by changes in the concentration of DA in ex- 
tracellular fluid, but only following the A M P H  chal- 
lenge (Fig. 3A). During baseline there was no differ- 
ence between saline- and AMPH-pretreated animals 
in the extracellular concentrations of DA in ventral 
striatum (in saline-pretreated rats it averaged 57.6 _+ 
11.8 (S.E.M.) fmol/min and in AMPH-pre t rea ted  
rats 56.6 + 6.7 fmol/min; values corrected for recov- 
ery; Fig. 3A). The challenge injection of AMPH pro- 
duced a significant increase in the extracellular con- 
centrations of DA in both saline- and AMPH-pre-  
treated animals, and this peaked during the second 
2(1 min interval in both groups. However,  the 
AMPH-evoked rise in extracellular DA was signifi- 
cantly greater in AMPH-pretreated animals than in 
saline-pretreated animals (Fig. 3A). The two pre- 
t reatment groups did not differ significantly during 
the first 20 rain interval following the AMPH chal- 
lenge, but extracellular DA concentrations rose to a 
significantly higher peak in AMPH-pre t rea ted  ani- 
mals and this difference persisted for the next 80 rain. 
By the end of the test session extracellular fluid con- 
centrations of DA had fallen to slightly below base- 
line levels in both groups, and at this time there was 
again no difference between the groups (Fig. 3A). 
AMPH pretreatment also changed the extracellu- 
lar concentrations of DOPAC and HVA (Fig. 3B,C). 
The extracellular concentration of DOPAC was sig- 
nificantly higher in AMPH-pretreated than in saline- 
pretreated animals. A two-way ANOVA for repeat- 
ed measures that included all 11 sample intervals re- 
suited in a significant effect of pretreatment condi- 
tion (P = 0.025; Fig. 3B), but no significant interac- 
tion (F < 1.0), suggesting the two groups differed at 
all points in time (including baseline). However, a t- 
test on just the baseline values did not reach statis- 
tical significance, probably because of greater varia- 
tion in extracellular fluid DOPAC concentrations 
during baseline than following the AMPH challenge 
(see S.E.M. bars on Fig. 3B). There was also a sig- 
nificant effect of time (P < 0.001) because the 
AMPH challenge caused a large decline in extracel- 
lular DOPAC concentrations, which was maximal by 
the third 20 min interval after AMPH and persisted 
throughout the test session. The absence of a signifi- 
cant pretreatment × time interaction indicates that 
the rate of decline in DOPAC was the same for 
AMPH and saline-pretreated animals. AMPH pre- 
treatment had a similar effect on extracellular HVA 
concentrations, in that the average concentrations 
were higher in AMPH-pretreated animals than in sa- 
line controls at all points in time; but this difference 
did not reach statistical significance (P = 0.11). The 
decline in HVA produced by the AMPH challenge 
was more gradual than for DOPAC (Fig. 3), but pro- 
ceeded at the same rate in AMPH and saline-pre- 
treated groups (the effect of time was significant, P < 
0.001, but the interaction term was non-significant). 
Neither AMPH pretreatment (P = 0.24) nor the 
AMPH challenge (F < 1.0) had a significant effect on 
the concentration of 5-HIAA in ventral striatal extra- 
cellular fluid (Fig. 3D). 
Histology. The location of each dialysis probe was 
estimated from examination of the histological sec- 
tions. Neurochemical data from one rat were excluded 
because its probe was not in the ventral striatum. The 
remaining probes all extended ventrally into the ol- 
factory tubercle; the deepest to 9.22 mm ventral from 
bregma (all coordinates refer to those on horizontal 
sections in Paxinos and Watson26). The first 250/~m 
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Fig. 4. Schematic drawing of the anterior portion of a hori- 
zontal section of rat brain adapted from Paxinos and Watson 26 
showing the area traversed by the dialysis probes. The hori- 
zontal plane represented by this plate (Fig. 95 in Paxinos and 
Watson 26) is 7.6 mm ventral from bregma. Closed circles repre- 
sent probes from amphetamine-pretreated animals and open 
circles probes from saline-pretreated animals. The diameter of 
each circle is drawn to scale, and thus illustrates the approxi- 
mate diameter of a dialysis probe relative to the nucleus accum-. 
hens. Abbreviations: AcbC, nucleus accumbens, core; AcbSh, 
nucleus accumbens, shell; acp, anterior commissure, posterior; 
AOP, anterior olfactory nucleus, posterior; BST, bed nucleus 
of the stria terminalis; CPu, caudate putamen; f, fornix; 
MnPO, median preoptic nucleus; Pir, piriform cortex; SI, sub- 
stantia innominata; SM, nucleus of the stria medullaris; Tu, ol- 
factory tubercle; VDB, nucleus vertical limb diagonal band; 
VP, ventral pallidum; 3V, third ventricle. 
of each probe consisted of the epoxy plug, and the ac- 
tual dialysis region extended for 2.0 mm dorsally 
from the top of the plug. In the majority of animals 
the region sampled extended from 8.35 mm to 6.35 
mm ventral from bregma, in the dorsal-ventral 
plane. On average, approximately 12% of the dialy- 
sis surface was located in the olfactory tubercle and 
the cell bridges of the ventral striatum and 88% in the 
nucleus accumbens. Fig. 4 shows the location of the 
probes as they traversed the plane of a horizontal sec- 
tion located 7.60 mm ventral to bregma. In summary, 
the probes sampled the ventral striatum 1'x6 consisting 
primarily of the nucleus accumbens, and to a lesser 
extent the olfactory tubercle and cell bridges of the 
ventral striatum. The dialysis fibers did not extend 
dorsally into the caudate-putamen. 
DISCUSSION 
To summarize the major findings: (a) pretreat- 
ment with escalating doses of AMPH produced a 
large and persistent (15-20 days) hypersensitivity to 
the motor stimulant effects of an AMPH challenge; 
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(b) behavioral sensitization was accompanied by an 
enhancement in ventral striatal DA neurotransmis- 
sion in vivo; (c) AMPH pretreatment was not neuro- 
toxic, in that regional brain concentrations of DA 
and 5-HT were normal in postmortem tissue; and (d) 
AMPH pretreatment did not produce persistent 
(25-30 days) alterations in spontaneous motor activi- 
ty across the day-night cycle. The implications of 
these findings are discussed below. 
Behavior 
Spontaneous motor activity over the light-dark 
cycle was relatively normal in AMPH-pretreated rats 
by 25-30 days after the cessation of drug treatment. 
The only difference between saline and AMPH-pre- 
treated animals was that the former group showed an 
increase in activity towards the end of the dark 
period and the latter group did not. This resulted in 
slightly lower activity scores in AMPH-pretreated 
rats during the last couple of hours before lights-on. 
In contrast, Robinson and Camp 33 reported that the 
same escalating dose regimen as used here produced 
a significant decrease in nocturnal activity. But Rob- 
inson and Camp 33 measured activity 8-12 days fol- 
lowing the cessation of drug treatment, and in the 
present study animals were withdrawn for 25-30 
days. A comparison of the two studies suggests that 
the hypoactivity seen following withdrawal from this 
escalating dose regimen 33 largely dissipates in about 
one month. 
Despite relatively normal levels of spontaneous 
motor activity there was a large effect of AMPH pre- 
treatment on the behavioral response to a challenge 
injection of AMPH. In control animals the AMPH 
challenge produced general hyperactivity. In 
AMPH-pretreated animals it produced intense fo- 
cused stereotyped behavior, and a multiphasic pat- 
tern of locomotion. Thus, in AMPH pretreated rats 
the AMPH challenge produced a behavioral syn- 
drome characteristic of a hyperdopaminergic 
state  39"41, indicating that even after 21 days of with- 
drawal AMPH-pretreated animals were still highly 
sensitized. The behavioral response to a challenge 
with 2.0 mg/kg of AMPH seen here was very similar 
to that reported previously in animals withdrawn 
from escalating dose AMPH treatment for only 12 
days 33. This suggests that the hypersensitivity to the 
motor stimulant effects of AMPH persists unabated 
for at least 21 days after the last pretreatment injec- 
tion, and perhaps for much longer 3°. 
The behavioral hypersensitivity to an AMPH chal- 
lenge reported here was qualitatively similar to the 
effects of a more typical constant low dose regimen, 
as were the neurochemical sequelae 4'5'3°'39"41'42. In 
contrast, the effects were quite different from those 
produced by neurotoxic treatment regimens (ref. 30 
for review). The escalating dose regimen mimics to 
some extent the pattern of drug use seen in addicts, 
and therefore, the data further support the idea that 
the sensitization phenomenon provides a good ani- 
mal model for studying the neurobiology of AMPH 
psychosis 3°'4° - whether sensitization is induced by 
pretreatment with constant low doses or escalating 
doses of AMPH. 
Nevertheless, there are differences between con- 
stant low dose and escalating dose regimens. We can- 
not directly compare the magnitude of the behavioral 
syndrome reported here with the syndrome produced 
by a lower constant dose regimen, because of meth- 
odological differences in how behavior was quanti- 
fied. But differences in the amount of individual vari- 
ation suggest that treatment with escalating doses 
produces much more intense sensitization. In the 
present study every animal pretreated with AMPH 
showed vigorous stereotyped behavior, as indicated 
by the cessation of locomotor activity between about 
50 and 90 rain after the challenge injection of 2.0 
mg/kg (Fig. 5). In comparison, when Camp and Rob- 
90 
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Fig. 5. Left: the frequency of crossovers in the 8 individual fe- 
male rats pretreated with escalating doses of amphetamine dur- 
ing the twenty 10 min intervals following a challenge injection 
of 2.0 mg/kg of amphetamine. Each line represents data from 
one rat. Right: the average frequency of crossovers for the 
same 8 rats (closed symbols) and for saline-pretreated rats (re- 
plotted from Fig. 2 for ease of comparison). Note that all am- 
phetamine-pretreated rats showed a triphasic response pat- 
tern. 
inson ~ pretreated rats with one injection of 2.6 mg/kg 
of A M P H  every 3 days, for a total of 9 injections, and 
also challenged them with 2.0 mg/kg, there was a 
great deal of individual variation in response to the 
challenge (Fig. 6). In the latter instance some ani- 
mals showed stereotyped behavior and a multiphasic 
pattern of locomotion, but others showed only hyper- 
activity. Marked individual variation in sensitization 
is typical of the constant low dose regimen, as dis- 
cussed recently by Segal and Kuczenski 41 and Camp 
and Robinson 4'5 (see ref. 28 for review). 
The relative absence of  individual variation in be- 
havioral response to a challenge seen with the esca- 
lating dose regimen may present some advantages in 
studying sensitization, especially in trying to identify 
reliable neural correlates of sensitization. The esca- 
lating dose regimen may also be advantageous for 
studying the complex pattern of changes that occur 
over time following withdrawal from repeated 
A M P H  use. For example, the hypoactivity seen early 
after withdrawal from an escalating dose regimen 33 
may be homologous to the dysphoric 'crash'  de- 
scribed in A M P H  addicts following withdrawal 7'2I. 
On the other hand, the escalating dose regimen may 
obscure important individual differences in the sus- 
ceptibility to sensitization 28. A constant low dose reg- 
imen may be more suitable for studying factors that 
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Fig. 6. Left: the frequency of crossovers in 8 individual female 
rats that were pretreated with one injection of 2.6 mg/kg of am- 
phetamine every 3 days, for a total of 9 injections, and then 3 
days after the last pretreatment injection were given a chal- 
lenge injection of 2.0 mg/kg (data from ref. 5). Data are shown 
for twenty-four 5 rain intervals after the amphetamine chal- 
lenge, and each line represents data from l animal. The eight 
animals were selected from a larger group of 15 animals to illus- 
trate the range of individual variation in response to the chal- 
lenge. Right: the average frequency of crossovers in the total 
group of 15 animals given this pretreatment regimen (replotted 
from Fig. 3F in Camp and RobinsonS). The individual variation 
illustrated here is typical of the sensitization produced by a con- 
stant low dose regimen (also see refs. 28, 41). Compare this 
with the level of individual variation illustrated in Fig. 5, 
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render some individuals very susceptible to sensitiza- 
tion and others relatively resistant. 
Neurochemistry 
In Experiment 1 animals were killed 33-34  days 
after the last injection of A M P H  and postmortem tis- 
sue concentrations of  monoamines were measured. 
There was no effect of A M P H  pretreatment on DA,  
D O P A C ,  HVA, 5-HT or 5 - H I A A  levels, or on me- 
tabolite/transmitter ratios, in the striatum, nucleus 
accumbens, frontal cortex or hypothalamus. This 
finding is important because it establishes that the es- 
calating dose regimen used here is not neurotoxic, in 
agreement with Robinson and Camp 33. However,  we 
reported previously that basal D A  metabolism is ele- 
vated in sensitized animals after shorter periods of 
withdrawal (9-12 days) 5'33, and in this experiment, in 
which animals were withdrawn for 33 days, no such 
changes were evident. A major  difference between 
our earlier studies 5~33 and the present study is the 
length of the withdrawal period, which suggests that 
sensitization-related changes in basal D A  metabo- 
lism do not persist over a month following with- 
drawal. This is not to say that D A  systems are normal 
after a month of withdrawal, because AMPH-st imu-  
lated striatal D A  release in vitro is still enhanced 2°'31. 
Perhaps measures of basal D A  activity, and especial- 
ly measures of D A  metabolism, are relatively insen- 
sitive indicators of sensitization-related changes in 
neural activity. After  a long period of withdrawal 
sensitization-related changes in neural activity may 
be apparent only following a challenge stimulus, such 
as reexposure to A M P H  3° or exposure to stress 32. 
This is consistent with the behavioral phenomenon,  
because after a month of  withdrawal sensitized ani- 
mals appeared quite normal b e h a v i o r a l l y -  until 
challenged (see above). Alternatively, the effects on 
DA metabolism reported previously could represent 
an exaggerated response to the stress associated with 
the decapitation procedure 33. 
The most important finding in the present study is 
that behavioral sensitization was accompanied by an 
enhancement in D A  neurotransmission in vivo. This 
is the first report on the long-term consequences of 
repeated A M P H  use in which behavioral measures 
and measures of D A  neurotransmission in the ventral 
striatum were obtained simultaneously from the 
same animals, both before and'after  an A M P H  chal- 
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lenge. There was no difference between AMPH- and 
saline-pretreated rats in the extracellular concentra- 
tion of DA during the resting state, just as there was 
no difference in behavior during the resting state. A 
challenge injection of AMPH elevated the extracel- 
lular concentration of DA in both groups, but to a sig- 
nificantly greater extent in AMPH-pretreated rats 
than in saline-pretreated controls. That is, the hyper- 
dopaminergic behavioral syndrome seen in sensi- 
tized animals following an AMPH challenge oc- 
curred in association with a significantly elevated ex- 
tracellular concentration of DA in the ventral stria- 
tum. 
The sensitization-related elevation in the extracel- 
lular concentration of DA seen following the AMPH 
challenge could be due to an increase in DA release, 
a decrease in DA reuptake, a decrease in DA metab- 
olism or a decrease in AMPH metabolism z2. De- 
creased AMPH metabolism could result in higher 
brain levels of AMPH in sensitized animals (and thus 
greater DA release), but the available evidence does 
not support this hypothesis s'3°. In fact, brain levels of 
AMPH are reduced in rats given escalating doses of 
meth-AMPH 3s. We can also eliminate decreased DA 
metabolism, because the extracellular concentra- 
tions of DA metabolites tended to be elevated in sen- 
sitized animals (also see refs. 5, 33). It is more diffi- 
cult to dissociate a change in reuptake from a change 
in release. There was no effect of AMPH pretreat- 
ment on the rate of decline of either DOPAC or HVA 
following the AMPH challenge. If the decline in 
DOPAC and HVA is due to AMPH's ability to block 
DA reuptake 22, resulting in less DA available for in- 
traneuronal metabolism, these results would suggest 
there was no sensitization-related change in reup- 
take. However, the decline in DOPAC produced by 
AMPH may not be due to AMPH's effect on reup- 
take, but to an AMPH-induced depletion of newly- 
synthesized cytosolic DA 2"51, thus removing, 'the 
main intraneuronal substrate for MAO and thereby 
reducing DA metabolite levels '52 (p.8). Therefore, 
the present data do not allow us to choose with confi- 
dence between release and reuptake hypotheses. 
Nevertheless, we favor the idea that the elevated ex- 
tracellular concentrations of DA seen in sensitized 
animals are due to an increase in the ability of AMPH 
to induce DA release, because: (a) a sensitization-re- 
lated enhancement in DA release has been reported 
in in vitro superfusion studies, in which the effects of 
reuptake are minimized29'31'49; and (b) one would ex- 
pect that a change in the reuptake carrier would re- 
sult in higher extracellular concentrations of DA dur- 
ing the resting state, and there were none. 
The data suggest that an enduring enhancement in 
DA neurotransmission, characterized by an increase 
in the releasability of DA, may be responsible for the 
enduring changes in behavior produced by past expe- 
rience with AMPH. It is worth noting in this regard 
that activation of DA systems appears to be neces- 
sary for the development of behavioral sensitization, 
because concomitant treatment with a DA antago- 
nist prevents sensitization to AMPH 23'47. The data 
presented here, however, do not allow us to ascertain 
the direction of putative cause-effect relations - -  i.e. 
does the increase in DA release cause the enhanced 
behavioral response, or vice versa? It is important to 
also consider, therefore, that a similar elevation in 
AMPH-stimulated DA release has been described in 
related studies involving the superfusion of dorsal 
striatal tissue in vitro 29'31A9. The in vitro experiments 
show that behavioral activation is not necessary to 
demonstrate a sensitization-related enhancement in 
DA release, thus supporting the idea that an eleva- 
tion in DA release is responsible for the development 
of behavioral sensitization. 
The mechanism responsible for the enhancement 
in DA release is unknown, but the effect does not ap- 
pear to be specific to AMPH-stimulated DA release. 
Castafieda et al. 3 recently reported that AMPH pre- 
treatment also enhances striatal DA release evoked 
by high KCI or electrical field stimulation in vitro 3. It 
has been hypothesized that a change in the intracellu- 
lar distribution of DA could account for both an in- 
crease in AMPH-evoked and depolarization-evoked 
DA release 3, but whether such a mechanism is in- 
volved in the phenomenon reported here remains to 
be determined. Whatever the mechanism, it is capa- 
ble of producing very long-lasting changes in behav- 
ior as a result of past experience, and therefore, may 
represent a type of neuronal plasticity common to 
other forms of behavioral adaptation (e.g. ref. 15). 
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